CFTR (CF transmembrane conductance regulator; HGNC:1884, NCBI Gene 1080) is the gene on chromosome 7q31.2 encoding the epithelial chloride-and-bicarbonate channel of the ABC-transporter family — the ion channel whose loss causes cystic fibrosis: dehydrated airway-surface liquid, thick mucus, chronic infection, and pancreatic insufficiency. The F508del mutation (a three-base deletion causing misfolding) is carried by ~1 in 25 people of European descent; the corrector-potentiator drug revolution (elexacaftor/tezacaftor/ivacaftor) restores the mutant channel's folding and function.
Approved Symbol
CFTR (HGNC:1884)
Chromosomal Locus
7q31.2
Encoded Product
CFTR — a 170-kDa phosphorylation-gated chloride channel (1,480 aa), see ion channels
Genomic organization: 27 exons encoding two membrane-spanning domains, two nucleotide-binding domains (ATP-gated), and the regulatory (R) domain with PKA phosphorylation sites — the domain anatomy that makes it a channel inside an ABC-transporter body.
Expression: All epithelia that secrete chloride — airway, sweat duct (the diagnostic sweat-chloride basis), pancreas, gut, vas deferens, and bile ducts; the tissue list is the disease's organ list.
Molecular Function & Pathways
Channel physiology: PKA phosphorylation of the R domain plus ATP binding/hydrolysis at the NBDs gate the pore; chloride (and bicarbonate) secretion draws sodium and water — the hydration layer that cilia need to clear mucus. Loss shifts epithelia toward sodium hyperabsorption and dehydrated secretions.
Mutation classes: Class I no-synthesis (nonsense), II misfolding/degradation (F508del), III gating (G551D), IV conductance, V reduced quantity — the classes that align with the drug classes (potentiators for gating, correctors for folding, amplifiers/read-through in development).
Clinical & Therapeutic Significance
Clinical genetics: Autosomal recessive; newborn screening by immunoreactive-trypsinogen plus DNA panels; F508del the commonest of >2,000 registered variants; sweat-chloride the functional diagnostic; congenital bilateral absence of the vas deferens as a genital-only CFTR phenotype.
Therapeutics: Ivacaftor (G551D's potentiator, 2012) then elexacaftor/tezacaftor/ivacaftor (2019) — highly effective modulator therapy for ~90% of patients, transforming a fatal childhood disease into a manageable chronic one; gene therapy and mRNA programs continuing for the rest.